Reforming Payment for Clinician-Administered Drugs — Most-Favored-Nation Pricing in Medicare Part B
T
Thomas J. Hwang
(Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston)
L
Lisa Clemans-Cope
(Health Policy Division, Urban Institute, Washington, DC)
A
Aaron S. Kesselheim
Article Details
Journal
New England Journal of Medicine
Volume / Issue
Vol. 394, Issue 18
Published
May 07, 2026
Pages
1774-1777
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
ISSN: 0028-4793 Social Sciences
Authors (3)
T
Thomas J. Hwang
Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston
L
Lisa Clemans-Cope
Health Policy Division, Urban Institute, Washington, DC
A
Aaron S. Kesselheim
Related Articles from this Journal
Doctor’s Dirty Little Secret — The Cost of Silence
Tara Khan
Aug 2026
10.1056/nejmp2515506
Obstructive Hypertrophic Cardiomyopathy
Julian-Kai Nishizono, Marohito Nakata
Aug 2026
10.1056/nejmicm2603868
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Martina Schatzl, Katharina A. Mayer et al.
Jul 2026
10.1056/nejmc2603853
Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
Jerry Avorn
Jul 2026
10.1056/nejmp2604841
Precision Intensification in Metastatic Prostate Cancer
Rana R. McKay
Jul 2026
10.1056/nejme2605582